Recent clinical data surrounding Retatrutide , specifically the high-dose formulation referred to as ZPHC, indicate a impressive benefit on body mass reduction and associated health illnesses . Researchers posit that this innovative agonist , influencing both GLP-1 and GIP receptors , could offer